Electromed, Inc. (AMEX:ELMD) Q4 2023 Earnings Call Transcript

Jim Cunniff: Well, thank you for participating today and your continued support of Electromed, everyone that’s on the call. I’d like to mention that Electromed will be hosting an investor meetings in person and virtually in early September. And if you’d like more information or you’d like to participate, please contact our Investor Relations contacts at ICR Westwick. Additionally, I’m also excited to be at the helm of this growing company and look forward to continuing to execute against our strategic growth plans and scale Electromed’s business. Our expanding sales team continues to operate at a high level and we expect our new Clearway SmartVest to be a catalyst to growth as we offer a highly effective therapy for bronchiectasis sufferers in a smaller, lighter and easier-to-use package.

We’re committed to improving operational efficiency and are proactively working to blunt any potential effects from the expiration of the CMS waiver. And finally, we will continue to generate awareness by continuing to build on our library of clinical data supporting HFCWO as an effective therapy for bronchiectasis in fiscal 2024. Electromed delivered a strong year in fiscal 2023, and we’re well positioned to deliver another in fiscal year 2024. Thank you again for your time today. Much appreciated.

Operator: Ladies and gentlemen, this does conclude today’s teleconference. Thank you for your participation. You may disconnect your lines at this time, and have a wonderful day.